mrz-99030
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2012 (NCT01714960)
Timeline
Indications
Studied for
Mechanism of action
- Amyloid beta A4 proteinINHIBITOR
APP inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 2-(2-amino-3-(1h-indol-3-yl)propionylamino)-2-methylpropionic acid
- mrz-99030
- mrz-99030
- mrz-99030
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06659549 | Phase 2 | Dec 16, 2024 | Galimedix Therapeutics Inc, Lexitas |
| NCT01714960 | Phase 1 | Oct 1, 2012 | Merz |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Galimedix Therapeutics Inc | For profit | 1 | 1 | 1 | 2024 |
| Lexitas | For profit | 1 | 0 | 1 | 2024 |
| Merz | For profit | 1 | 1 | 1 | 2012 |
3 organizations
Page 1 / 1